Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS

High-dose, posttransplantation cyclophosphamide (PTCy) reduces severe graft-versus-host disease (GVHD) after allogeneic blood or marrow transplantation (alloBMT), but the impact of PTCy on long-term, disease-specific outcomes is unclear. We conducted a retrospective study of 209 consecutive adult pa...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood
Päätekijät: Kanakry, Christopher G., Tsai, Hua-Ling, Bolaños-Meade, Javier, Smith, B. Douglas, Gojo, Ivana, Kanakry, Jennifer A., Kasamon, Yvette L., Gladstone, Douglas E., Matsui, William, Borrello, Ivan, Huff, Carol Ann, Swinnen, Lode J., Powell, Jonathan D., Pratz, Keith W., DeZern, Amy E., Showel, Margaret M., McDevitt, Michael A., Brodsky, Robert A., Levis, Mark J., Ambinder, Richard F., Fuchs, Ephraim J., Rosner, Gary L., Jones, Richard J., Luznik, Leo
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2014
Aiheet:
Transplantation
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4263989/
https://ncbi.nlm.nih.gov/pubmed/25316679
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-07-587477
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia